Previous 10 | Next 10 |
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tre...
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatme...
Gainers: Canoo ( GOEV ) +28% . Kaspien Holdings ( KSPN ) +18% . Clever Leaves Holdings ( CLVR ) +20% . Yatsen Holding ( YSG ) +17% . Lucira Health ( LHDX ) +17% . Revelation Biosciences ( REVB ) +16% . Kopin Corpo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Fit Ztudio / Shutterstock.com Ericsson (NASDAQ: ERIC ) stock isn’t doing so hot on Thursday as the company admits that inflation is starting to have an impact on its business . The company said...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The medical panel monitoring a Phase 3 trial of ContraFect’s (NASDAQ: CFRX ) treatment for antibiotic-resistant infections has stopped the trial after an “interim futility analysis,” the company...
Gainers: Biomerica ( BMRA ) +23% . Clene ( CLNN ) +22% . Gossamer Bio ( GOSS ) +11% . Revelation Biosciences ( REVB ) +10% . Nutriband ( NTRB ) +7% . Losers: ContraFect ( CFRX ) -81% . Novavax ( NVAX ) -1...
ContraFect ( CFRX ) -77% as data safety board recommends ending co's DISRUPT trial . BELLUS Health ( BLU ) -10% on pricing $153M stock offering in Canada, U.S. Telefonaktiebolaget LM Ericsson ( ERIC ) -9% on Q2 earnings release . Therape...
Shares of micro-cap biotech ContraFect ( NASDAQ: CFRX ) plunged ~76% after hours as a data safety board recommended that the company's DISRUPT trial be stopped. The Data Safety and Monitoring Board (DSMB) recommended such an action "because the conditional power of the...
YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-thre...
ContraFect ( CFRX ) -19% . United Maritime ( USEA ) -14% . Organovo Holdings ( ONVO ) -9% . Revelation Biosciences ( REVB ) -9% . Melco Resorts & Entertainment ( MLCO ) -7% after Chinese regulators close Macau casinos to cu...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023